Clinical trials: Metastatic Soft-tissue Sarcoma
Part 1, MELANOMA
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Protocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of PF-06801591 in previously treated adult patients with…
- Conditions
- Part 1, MELANOMA, SCCHN, OVCA
- Trial name
- NCT02573259
- Testing
- PF-06801591
- Where
- 67 sites in United States, Bulgaria and 5 more
- Volunteers
- 147 people
- Sponsor
- Pfizer
Adult Liposarcoma, Metastatic Liposarcoma
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
The purpose of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control sarcomas. The safety of this drug combination will also be studied.
- Conditions
- Adult Liposarcoma, Metastatic Liposarcoma, Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma
- Trial name
- NCT02357810
- Testing
- Pazopanib Hydrochloride, Oral Topotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 8 sites in United States
- Volunteers
- 178 people
- Sponsor
- Northwestern University
Bone Sarcoma, Femur Fracture
Dalteparin in Preventing DVT in Participants With Cancer
This trial studies how well dalteparin works in preventing deep vein thrombosis (DVT) (blood clots) in participants with cancer. Dalteparin is a blood thinner that can treat blood clots and may prevent them from forming.
- Conditions
- Bone Sarcoma, Femur Fracture, Lymphoma, Metastatic Neoplasm
- Trial name
- NCT00525057
- Testing
- Dalteparin
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma
Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma
This is an international, multi-centre, single arm Bayesian designed phase 2 study to identify and determine the safety and activity of anti-IGF-1/IR inhibition in patients with relapsed and/or refractory ESFT.
- Trial name
- LINES (NCT02546544)
- Testing
- Linsitinib
- Where
- 5 sites in France, Germany and 3 more
- Volunteers
- 16 people
- Sponsor
- University of Oxford
Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma
Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas
This phase I/II trial studies the side effects and best dose of nab-sirolimus and how well it works when given together with pazopanib hydrochloride in treating participants with nonadipocytic soft tissue sarcomas that has spread…
- Conditions
- Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
- Trial name
- NCT03660930
- Testing
- Sirolimus Albumin-bound Nanoparticles, Pazopanib hydrochloride
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Washington
Metastatic Leiomyosarcoma, Metastatic Liposarcoma
Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
This phase I/II studies the side effects of avelumab and trabectedin and how well they work in treating patients with leiomyosarcoma or liposarcoma that has spread to other places in the body (metastatic) or cannot be removed by…
- Conditions
- Metastatic Leiomyosarcoma, Metastatic Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma
- Trial name
- NCT03074318
- Testing
- Avelumab, Trabectedin
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Fred Hutchinson Cancer Center
Solid Tumors, Head and Neck Carcinoma
Milademetan in Advanced/Metastatic Solid Tumors
Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that…
- Conditions
- Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma
- Trial name
- NCT05012397
- Testing
- RAIN-32
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rain Oncology Inc
Advanced Malignant Neoplasm, Castleman Disease
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body…
- Conditions
- Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease
- Trial name
- NCT01552434
- Testing
- Bevacizumab, Cetuximab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- M.D. Anderson Cancer Center
Sarcoma
Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
RATIONALE: Drugs used in chemotherapy, such as vinblastine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00061893
- Testing
- celecoxib, cyclophosphamide, doxorubicin hydrochloride
- Where
- 101 sites in United States, Australia and 2 more
- Volunteers
- 38 people
- Sponsor
- Children's Oncology Group
Sarcoma
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
This is a Phase Ib/II experimental, open-label, dose escalation, active treatment study designed to determine the safety, tolerability, and recommended dose of the combination.
- Trial name
- GemTax (NCT01879085)
- Testing
- Docetaxel, Gemcitabine, Vorinostat
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Melissa Burgess, MD
Sarcoma
Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas
The purpose of this study is to explore how this cancer is affected by a new medication, cetuximab. Cetuximab is directed towards a protein called EGFR (epidermal growth factor receptor), that is found in some types of cancer.
- Trial name
- NCT00148109
- Testing
- Cetuximab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Michigan Rogel Cancer Center
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating…
- Conditions
- Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma
- Trial name
- NCT01154452
- Testing
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Soft Tissue Sarcoma
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma
The main purpose of this study is to evaluate the efficacy of the combination of doxorubicin plus the study drug known as olaratumab versus doxorubicin plus placebo in participants with advanced or metastatic soft tissue sarcoma.
- Trial name
- ANNOUNCE (NCT02451943)
- Testing
- Olaratumab, Doxorubicin
- Where
- 114 sites in United States, Argentina and 23 more
- Volunteers
- 509 people
- Sponsor
- Eli Lilly and Company
Ewing's Sarcoma, Rhabdomyosarcoma
A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas
This is a single arm study. The tumor specimen is analyzed for the presence of a fusion protein which corresponds to available peptides.
- Trial name
- NCT00001566
- Testing
- therapeutic autologous dendritic cells, indinavir sulfate, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Adult Angiosarcoma, Adult Epithelioid Sarcoma
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
This phase II trial is studying how well sorafenib works in treating patients with metastatic, locally advanced, or recurrent sarcoma.
- Conditions
- Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Leiomyosarcoma, Adult Malignant Fibrous Histiocytoma
- Trial name
- NCT00245102
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer, Melanoma (Skin)
Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Conditions
- Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer
- Trial name
- NCT00550654
- Testing
- questionnaire administration, 3-dimensional conformal radiation therapy, hypofractionated radiation therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Sarcoma, Metastatic Disease
Stereotactic Radiation Therapy for Pediatric Sarcomas
The stereotactic body radiation therapy (SBRT) literature focuses on clinical outcomes in the adult population. However, SBRT has a particularly strong rationale for application in pediatrics given that high biologically…
- Conditions
- Sarcoma, Metastatic Disease, Bony Sites
- Trial name
- NCT01763970
- Testing
- SBRT
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
SCLC, Malignant Melanoma
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA…
- Conditions
- SCLC, Malignant Melanoma, Sarcoma, High Risk Neuroblastoma
- Trial name
- NCT05130255
- Testing
- GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi), GD2-SADA (3 mg/kg) 177Lu-DOTA (30 mCi), GD2-SADA (0.3 mg/kg) 177Lu-DOTA (200 mCi)
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Y-mAbs Therapeutics
Leukemia, Lymphoma
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
RATIONALE: Giving an infusion of donor lymphocytes may be able to kill cancer cells in patients with hematologic cancer that has come back after a donor stem cell transplant.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00534118
- Testing
- donor lymphocytes
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Roswell Park Cancer Institute
Soft Tissue Sarcoma
Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma
Primary Objectives 1. To evaluate the Response Rate (RR) for amrubicin in patients with metastatic or advanced sarcoma as first line therapy. 2. To evaluate Progression Free Survival (PFS). Secondary Objectives 1.
- Trial name
- ARSARC-PI-0010 (NCT01259375)
- Testing
- Amrubicin
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Utah